[1]刘萍△,王豪勋.非小细胞肺癌组织中RRM1的表达与含吉西他滨方案耐药的关系[J].郑州大学学报(医学版),2011,(06):876.
 LIU Ping,WANG Haoxun.Relationship between RRM1 expression in non smallcell lung cancer tissue and gemcitabinecontaining regimen resistance[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(06):876.
点击复制

非小细胞肺癌组织中RRM1的表达与含吉西他滨方案耐药的关系
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2011年06期
页码:
876
栏目:
论著
出版日期:
2011-11-20

文章信息/Info

Title:
Relationship between RRM1 expression in non smallcell lung cancer tissue and gemcitabinecontaining regimen resistance
作者:
刘萍王豪勋
郑州大学第二附属医院肿瘤科 郑州 450014
Author(s):
LIU PingWANG Haoxun
Department of Oncology, the Second Affiliated Hospital, Zhengzhou University, Zhengzhou 450014
关键词:
非小细胞肺癌核糖核苷酸还原酶M1吉西他滨耐药
Keywords:
non smallcell lung cancer ribonucleotide reductase M1 gemcitabine drug resistance
分类号:
R734.2
摘要:
目的:探讨晚期非小细胞肺癌(NSCLC)组织中核糖核苷酸还原酶M1(RRM1)的表达与含吉西他滨方案耐药的关系。方法:将108例NSCLC患者均分为2组,试验组采用吉西他滨/顺铂(GP)方案治疗:吉西他滨1 000 mg/m2第1、8天静脉滴注,顺铂25 mg/m2第1~3天静脉滴注,21 d为1个周期;对照组采用紫杉醇/顺铂(TP)方案治疗:紫杉醇150 mg/m2第1天静脉滴注,顺铂25 mg/m2第1~3天静脉滴注,21 d为1个周期。2个周期后评价疗效。应用免疫组化SP法检测2组患者NSCLC组织中RRM1的表达并分析其与含吉西他滨方案耐药的关系。结果:RRM1高表达与GP方案化疗耐药有关:GP方案化疗耐药组RRM1的高表达率为62.5%,明显高于敏感组(30.0%)(χ2=5.704,P=0.017)。RRM1高表达与TP方案化疗耐药无关(χ2=0.557,P=0.456)。结论:NSCLC组织中RRM1的表达升高与含吉西他滨方案耐药有关。
Abstract:
Aim:To explore the relationship between the expression of RRM1 in non smallcell lung cancer(NSCLC) tissue and gemcitabinecontaining regimen resistance.Methods:A total of 108 cases of NSCLC were allocated into 2 groups:54 cases were treated with gemcitabine and cisplatin(GP group),54 cases were treated with paclitaxel and cisplatin(TP group). All patients had received 2 cycles chemotherapy,and 21 days was a cycle.The expression of RRM1 in 108 cases of NSCLC tissue was detected by immunohistochemistry method and the relationship between the RRM1 expression and gemcitabincontaining regimen resistance was analyzed.Results:The high expression of RRM1 was associated with GP regimen resistance in NSCLC.The high expression rate of RRM1 in chemoresistant group was 62.5%, that of chemosensitive group was 30.0%,and the difference was significant(χ2=5.704,P=0.017).The high expression of RRM1 was not associated with TP regimen resistance in NSCLC(χ2=0.557,P=0.456).Conclusion:The high expression of RRM1 in NSCLC is related to gemcitabinecontaining regimen resistance.

参考文献/References:

[1]Ramalingam S,Belani C.Systemic chemotherapy for advanced nonsmall cell lung cancer:recent advances and future directions[J].Oncologist,2008,13(Suppl 1):5 [2]任小晶,孙玲,巩宏涛,等.吉西他滨对白血病细胞系HL60细胞的抑制作用[J].实用儿科临床杂志,2008,23(15):1170 [3]Greta JL,Keith B.Mechanisms of action of cancer chemotherapeutic agents[M].London:Nature Publishing Group,2002:1271 [4]Gautam A,Li ZR,Bepler G.RRM1induced metastasis suppression through PTENregulated pathways[J].Oncogene,2003,22(14):2135 [5]Rha SY,Jeung HC,Choi YH,et al.An association between RRM1 haplotype and gemcitabineinduced neutropenia in breast cancer patients[J].Oncologist,2007,12(6):622 [6]Davidson JD,Ma L,Flagella M,et al.An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in nonsmall cell lung cancer cell lines[J].Cancer Res, 2004, 64(11):3761 [7]Ceppi P,Volante M,Novelo S,et al.ERCC1 and RRM1 gene expression but not EGFR are predictive of shorter survival in advanced nonsmallcell lung cancer treated with cisplatin and gemcitabine[J]. Ann Oncol, 2006, 17(12):1818 [8]李张云,邓觐云,黄传生,等.非小细胞肺癌RRM1蛋白表达与吉西他滨体外药敏相关性的研究[J].江西医药,2009,44(11):1074

相似文献/References:

[1]夏宗江,赵松,崔广晖#.非小细胞肺癌组织中Survivin、Bcl2及PCNA蛋白的表达[J].郑州大学学报(医学版),2010,(02):322.
[2]李甸源,高松涛,石永刚,等.非小细胞肺癌脑转移立体定向X刀放疗联合全脑照射100例[J].郑州大学学报(医学版),2009,(04):877.
[3]韩娜,王健,张中冕.培美曲塞联合顺铂治疗晚期非小细胞肺癌18例[J].郑州大学学报(医学版),2010,(05):876.
[4]王珍珍),周云)#,王文玉),等.非小细胞肺癌组织中Survivin蛋白的表达[J].郑州大学学报(医学版),2010,(04):653.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(06):653.
[5]马望,樊青霞,王留兴#,等.非小细胞肺癌患者化疗前后血清IGF1和IGFBP3水平的变化[J].郑州大学学报(医学版),2010,(04):663.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(06):663.
[6]葛辰蕾),李醒亚),尚可),等.非小细胞肺癌预后影响因素分析*[J].郑州大学学报(医学版),2011,(02):216.
 GE Chenlei),LI Xingya),SHANG Ke),et al. Analysis of prognostic factors for nonsmall cell lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(06):216.
[7]刘瑜,王娜,冯斐斐,等.非小细胞肺癌组织中CD68与cJun蛋白的表达*[J].郑州大学学报(医学版),2011,(06):861.
 LIU Yu,WANG Na,FENG Feifei,et al.Expressions of CD68 and cJun proteins in nonsmall cell lung cancer tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(06):861.
[8]刘天舟)△,张琳),王庆芳).非小细胞肺癌患者血清CA153、CA242及CYFRA211水平测定[J].郑州大学学报(医学版),2012,(01):113.
 LIU Tianzhou,ZHANG Lin,WANG Qingfang.Determination of CA153,CA242 and CYFRA211 in serum of patients with nonsmall cell lung cancer[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(06):113.
[9]刘少平△,钱文军,茅卫东.恩度对晚期非小细胞肺癌患者血清VEGF和bFGF的影响*[J].郑州大学学报(医学版),2013,(01):144.
[10]孙丽娟△,付群,李宏云,等.EGFR、KRAS、BRAF、PI3K基因突变与非小细胞肺癌靶向药物治疗的关系[J].郑州大学学报(医学版),2013,(01):147.

备注/Memo

备注/Memo:
△女,1971年11月生,硕士,副主任医师,研究方向:恶性肿瘤的防治,Email:lp1232717@sina.com
更新日期/Last Update: 1900-01-01